Background Evaluation and interpretation of the literature on obstructive sleep apnea (OSA)
allows for consolidation and determination of the key factors important for clinical …

Background Untreated OSA is associated with impaired health-related quality of life (QoL)
and excessive daytime sleepiness, which have been shown to improve with treatment. The …

Study objective To synthesize evidence from available studies on the relative efficacies of
continuous positive airway pressure (CPAP), mandibular advancement device (MAD) …

Abstract Treatment of OSA with CPAP is currently the recommended treatment and has the
greatest evidence of efficacy on AHI, symptoms and comorbidities. Symptomatic patients …

Background Excessive daytime sleepiness (EDS) in individuals with OSA syndrome
persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective …

Background Excessive sleepiness (ES) is a common symptom of OSA, which often persists
despite primary OSA therapy. This phase III randomized withdrawal trial evaluated …

Pharmacotherapy represents a desirable potential therapeutic alternative for patients with
obstructive sleep apnoea (OSA). We aimed to summarize evidence on the efficacy of …

Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive
sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a …

There is now widespread recognition within the world of sleep medicine of the increasing
importance of dental sleep medicine and, in particular, the role of oral appliance therapy …

The primary oral appliance (OA) used in obstructive sleep apnea (OSA) treatment is the
mandibular advancement device (MAD). MADs may be either an over-the-counter stock …